Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

Trial Details

NCT ID
NCT06333262
Phase
PHASE2
Sponsor
Inhye Ahn
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Pirtobrutinib
  • Obinutuzumab
Locations (sample)
  • Scarborough, Maine, United States|43.57814,-70.32172
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Meet 2018 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for the diagnosis of chronic lymphocytic leukemia (CLL) or smal…
  • Presence of measurable disease (absolute lymphocyte count \> 5,000/µL, palpable or measurable lymph nodes ≥1.5cm on imaging, or bone marrow involve…
  • No prior systemic therapy for CLL or SLL.
  • Currently have an indication for treatment as defined by the following 2018 IWCLL guidelines

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →